This research, utilizing real-world data from the FAERS database, confirmed known adverse reactions to ofatumumab, including injection site reactions, upper respiratory tract infections, headache, and decreased levels of immunoglobulin M (IgM). Here, CD40LG is linked to Recurrent upper respiratory tract infections.